Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (24), 7675-7685
- https://doi.org/10.3748/wjg.v20.i24.7675
Abstract
Patients with hepatocellular carcinoma (HCC) often experience hepatic morbidity. Hepatitis B virus (HBV) reactivation is well documented as a serious hepatic morbidity during anti-cancer therapy. Reported rates of HBV reactivation in chronic carriers with HCC undergoing chemotherapy range from 4%-67%. Apart from chemotherapy, HBV reactivation has been increasingly identified in settings of hepatectomy and local ablation therapies. The rates of HBV reactivation vary with different levels of immunosuppression and depend on treatment, viral factors, and patient characteristics. The principal concern relating to reactivation is that a substantial proportion of patients with reactivation suffer from liver dysfunction during therapy, which often leads to disruption of planned, potentially life-prolonging treatments, adversely affecting the patients’ final outcome. The first step in the management of HBV reactivation is identification of patients at risk of reactivation by testing for HBV serology prior to commencing anti-cancer therapy. Although it is a serious complication, HBV reactivation is preventable with prophylactic anti-HBV drugs. Multiple publications have shown the benefit of prophylactic or preemptive antiviral therapy in this setting and justified such an approach before the start of therapy. Given the tumors and underlying cirrhosis, long-term use of antivirals with high potency and low risk of resistance is recommended in patients with HCC. This topic review will summarize the epidemiology, pathogenesis, and clinical issues related to HBV reactivation in HCC patients, and will discuss proper management against HBV reactivation during anti-cancer therapy for HCC.Keywords
This publication has 51 references indexed in Scilit:
- Posthepatectomy HBV Reactivation in Hepatitis B–Related Hepatocellular Carcinoma Influences Postoperative Survival in Patients With Preoperative Low HBV-DNA LevelsAnnals of Surgery, 2013
- Antiviral therapy decreases viral reactivation in patients with hepatitis B virus–related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trialJournal of Viral Hepatitis, 2012
- Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular CarcinomaJournal of Immunology Research, 2012
- Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinomaHepatology Research, 2011
- Management of hepatocellular carcinoma: An updateJournal of Hepatology, 2011
- Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphomaInternational Journal of Hematology, 2009
- Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinomaHepatology International, 2007
- Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver diseaseGastroenterology, 2001
- Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantationLiver Transplantation, 2001
- Reactivation of Viral Replication After Liver Resection in Patients Infected With Hepatitis B VirusAnnals of Surgery, 2001